These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 23975841

  • 1. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
    Rasch MG, Helleberg M, Feldt-Rasmussen B, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Gerstoft J, Obel N.
    Nephrol Dial Transplant; 2014 Jun; 29(6):1232-8. PubMed ID: 23975841
    [Abstract] [Full Text] [Related]

  • 2. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
    Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, Gerstoft J, Obel N.
    Scand J Infect Dis; 2012 Sep; 44(9):689-96. PubMed ID: 22680981
    [Abstract] [Full Text] [Related]

  • 3. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
    Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD, EuroSIDA Study Group.
    AIDS; 2010 Jul 17; 24(11):1667-78. PubMed ID: 20523203
    [Abstract] [Full Text] [Related]

  • 4. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
    Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, Ambuhl P, Wuthrich RP, Moch H, Varga Z.
    Virchows Arch; 2007 Jun 17; 450(6):665-70. PubMed ID: 17464512
    [Abstract] [Full Text] [Related]

  • 5. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
    Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G, Groupe D’epidémiologie Clinique du Sida en Aquitaine (Gecsa).
    PLoS One; 2013 Jun 17; 8(6):e66223. PubMed ID: 23776637
    [Abstract] [Full Text] [Related]

  • 6. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.
    Eur J Clin Pharmacol; 2007 Oct 17; 63(10):935-40. PubMed ID: 17665183
    [Abstract] [Full Text] [Related]

  • 7. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
    Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Perri GD, Lanzafame M, Penco G.
    J Acquir Immune Defic Syndr; 2009 Nov 01; 52(3):431-2. PubMed ID: 19858926
    [No Abstract] [Full Text] [Related]

  • 8. High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
    Bonjoch A, Juega J, Puig J, Pérez-Alvarez N, Aiestarán A, Echeverría P, Pérez V, Clotet B, Romero R, Bonet J, Negredo E.
    AIDS Patient Care STDS; 2014 Oct 01; 28(10):524-9. PubMed ID: 25238104
    [Abstract] [Full Text] [Related]

  • 9. Smoking and renal function in people living with human immunodeficiency virus: a Danish nationwide cohort study.
    Ahlström MG, Feldt-Rasmussen B, Legarth R, Kronborg G, Pedersen C, Larsen CS, Gerstoft J, Obel N.
    Clin Epidemiol; 2015 Oct 01; 7():391-9. PubMed ID: 26357490
    [Abstract] [Full Text] [Related]

  • 10. Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
    D'Ettorre G, Zaffiri L, Ceccarelli G, Massetti AP, Mastroianni CM, Vullo V.
    J Chemother; 2008 Feb 01; 20(1):143-4. PubMed ID: 18343760
    [No Abstract] [Full Text] [Related]

  • 11. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
    Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM, Mocroft A, EuroSIDA in EuroCoord.
    HIV Med; 2013 Sep 01; 14(8):503-8. PubMed ID: 23590641
    [Abstract] [Full Text] [Related]

  • 12. Boosting HIV treatment options: good news, new challenges.
    Cahn P, Sued O.
    J Infect Dis; 2013 Jul 01; 208(1):4-6. PubMed ID: 23532095
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM, NEAT Unboosted Atazanavir Cohort Study Group.
    J Antimicrob Chemother; 2011 Oct 01; 66(10):2372-8. PubMed ID: 21821627
    [Abstract] [Full Text] [Related]

  • 14. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study.
    Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Obel N.
    AIDS; 2012 Jan 28; 26(3):285-93. PubMed ID: 22095195
    [Abstract] [Full Text] [Related]

  • 15. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET, Rosenblatt L, Myers J, Villasis-Keever A, Coumbis J.
    PLoS One; 2016 Jan 28; 11(12):e0166982. PubMed ID: 27941989
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
    Elion R, Cohen C, Ward D, Ruane P, Ortiz R, Reddy YS, Ebrahimi R, McColl D, Kearney B, Fisher A, Flaherty J, BATON Study Group.
    HIV Clin Trials; 2008 Jan 28; 9(4):213-24. PubMed ID: 18753116
    [Abstract] [Full Text] [Related]

  • 17. Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark.
    Helleberg M, Pedersen MG, Pedersen CB, Mortensen PB, Obel N.
    Lancet HIV; 2015 Aug 28; 2(8):e344-50. PubMed ID: 26423377
    [Abstract] [Full Text] [Related]

  • 18. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N.
    J Pharm Pract; 2012 Oct 28; 25(5):552-9. PubMed ID: 22551561
    [Abstract] [Full Text] [Related]

  • 19. [Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
    Vallecillo-Sánchez G, Guelar-Grimberg A, González-Mena A, Knobel-Freud H.
    Enferm Infecc Microbiol Clin; 2008 May 28; 26(5):316-7. PubMed ID: 18479652
    [No Abstract] [Full Text] [Related]

  • 20. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study.
    Rasmussen LD, Engsig FN, Christensen H, Gerstoft J, Kronborg G, Pedersen C, Obel N.
    AIDS; 2011 Aug 24; 25(13):1637-46. PubMed ID: 21646903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.